sr141716 has been researched along with oxidopamine in 9 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 2 (22.22) | 18.2507 |
| 2000's | 4 (44.44) | 29.6817 |
| 2010's | 2 (22.22) | 24.3611 |
| 2020's | 1 (11.11) | 2.80 |
| Authors | Studies |
|---|---|
| Le Fur, G; Poncelet, M; Rinaldi-Carmona, M; Soubrié, P; Souilhac, J | 1 |
| Sañudo-Peña, MC; Walker, JM | 1 |
| Asbrock, N; Ferrer, B; Giuffrida, A; Kathuria, S; Piomelli, D | 1 |
| de Miguel, R; Fernández-Ruiz, J; García-Arencibia, M; González, S; Ramos, JA; Scorticati, C | 1 |
| Fernández-Ruiz, J; Ferraro, L; García-Arencibia, M; Tanganelli, S | 1 |
| Cassin, J; Harris, O; Kelsey, JE | 1 |
| Aley-Medina, P; Anaya-Martínez, V; Avila-Costa, MR; Espinosa-Villanueva, J; García-Ruiz, R; Gutiérrez-Valdez, AL; Montiel-Flores, E; Reynoso-Erazo, L; Sánchez-Betancourt, J; Torres-Esquivel, C; Tron-Alvarez, R | 1 |
| Armentero, MT; Baqi, Y; Bonaventura, J; Canela, EI; Casadó, V; Cortés, A; Costa, G; Farré, D; Franco, R; Lanciego, JL; Lluís, C; Mallol, J; Martínez-Pinilla, E; McCormick, P; Müller, CE; Pinna, A; Sánchez, M; Simola, N | 1 |
| Binda, KH; Brooks, DJ; Chacur, M; Landau, AM; Real, CC | 1 |
9 other study(ies) available for sr141716 and oxidopamine
| Article | Year |
|---|---|
Intrastriatal injection of cannabinoid receptor agonists induced turning behavior in mice.
Topics: Analgesics; Animals; Benzoxazines; Cannabis; Corpus Striatum; Cyclohexanols; Dose-Response Relationship, Drug; Female; Injections; Mice; Morpholines; Naphthalenes; Neurons; Oxidopamine; Piperidines; Pyrazoles; Receptors, Cannabinoid; Receptors, Drug; Receptors, Neurokinin-2; Rimonabant; Stereoisomerism; Stereotyped Behavior | 1995 |
A novel neurotransmitter system involved in the control of motor behavior by the basal ganglia.
Topics: Action Potentials; Analgesics; Animals; Basal Ganglia; Benzoxazines; Bicuculline; Cannabinoids; Cyclohexanols; Dopamine; Dopamine Agonists; Electrophysiology; GABA Antagonists; gamma-Aminobutyric Acid; Morpholines; Motor Neurons; Naphthalenes; Nerve Degeneration; Neurotransmitter Agents; Oxidopamine; Piperidines; Pyrazoles; Quinpirole; Rats; Rimonabant; Sympatholytics; Thalamic Nuclei | 1998 |
Effects of levodopa on endocannabinoid levels in rat basal ganglia: implications for the treatment of levodopa-induced dyskinesias.
Topics: Animals; Antiparkinson Agents; Basal Ganglia; Behavior, Animal; Benzazepines; Benzoxazines; Brain Chemistry; Cannabinoid Receptor Modulators; Chromatography, High Pressure Liquid; Disease Models, Animal; Dopamine Antagonists; Drug Interactions; Dyskinesia, Drug-Induced; Dyskinesias; Endocannabinoids; Gas Chromatography-Mass Spectrometry; Levodopa; Male; Morpholines; Mouth; Naphthalenes; Oxidopamine; Parkinson Disease; Piperidines; Pyrazoles; Raclopride; Rats; Rats, Wistar; Receptor, Cannabinoid, CB1; Rimonabant; Substantia Nigra; Time Factors | 2003 |
Effects of rimonabant, a selective cannabinoid CB1 receptor antagonist, in a rat model of Parkinson's disease.
Topics: Adrenergic Agents; Analysis of Variance; Animals; Autoradiography; Brain; Brain Chemistry; Chromatography, High Pressure Liquid; Disease Models, Animal; Dopamine; Dose-Response Relationship, Drug; Drug Interactions; Electrochemistry; gamma-Aminobutyric Acid; Gene Expression; Glutamic Acid; In Situ Hybridization; Injections, Intraventricular; Male; Motor Activity; Oxidopamine; Parkinson Disease; Piperidines; Protein Binding; Pyrazoles; Rats; Rats, Sprague-Dawley; Reaction Time; Receptor, Cannabinoid, CB1; Rimonabant; RNA, Messenger; Rotarod Performance Test; Superoxide Dismutase; Superoxide Dismutase-1; Tyrosine 3-Monooxygenase | 2006 |
Enhanced striatal glutamate release after the administration of rimonabant to 6-hydroxydopamine-lesioned rats.
Topics: Animals; Corpus Striatum; Dose-Response Relationship, Drug; Drug Resistance; Extracellular Fluid; Glutamic Acid; Male; Microdialysis; Neural Inhibition; Oxidopamine; Parkinsonian Disorders; Piperidines; Presynaptic Terminals; Pyrazoles; Rats; Rats, Sprague-Dawley; Receptor, Cannabinoid, CB1; Rimonabant; Sympatholytics; Synaptic Transmission; Up-Regulation | 2008 |
The CB(1) antagonist rimonabant is adjunctively therapeutic as well as monotherapeutic in an animal model of Parkinson's disease.
Topics: Animals; Corpus Striatum; Disease Models, Animal; Hypokinesia; Levodopa; Male; Motor Activity; Oxidopamine; Parkinson Disease; Piperidines; Pyrazoles; Rats; Rats, Long-Evans; Receptor, Cannabinoid, CB1; Rimonabant | 2009 |
The combination of oral L-DOPA/rimonabant for effective dyskinesia treatment and cytological preservation in a rat model of Parkinson's disease and L-DOPA-induced dyskinesia.
Topics: Administration, Oral; Animals; Cannabinoid Receptor Antagonists; Corpus Striatum; Dihydroxyphenylalanine; Disease Models, Animal; Dopamine Agents; Drug Therapy, Combination; Dyskinesia, Drug-Induced; Male; Nerve Degeneration; Neuropil; Oxidopamine; Parkinsonian Disorders; Piperidines; Pyrazoles; Rats; Rimonabant; Substantia Nigra; Tyrosine 3-Monooxygenase | 2013 |
L-DOPA disrupts adenosine A(2A)-cannabinoid CB(1)-dopamine D(2) receptor heteromer cross-talk in the striatum of hemiparkinsonian rats: biochemical and behavioral studies.
Topics: Adenosine A2 Receptor Antagonists; Animals; Antiparkinson Agents; Cannabinoid Receptor Antagonists; Cholinesterase Inhibitors; Corpus Striatum; Disease Models, Animal; Dopamine Agents; Dose-Response Relationship, Drug; Drug Interactions; Functional Laterality; Levodopa; Male; Oxidopamine; Parkinsonian Disorders; Piperidines; Protein Binding; Pyrazoles; Rats; Rats, Sprague-Dawley; Receptor Cross-Talk; Rimonabant; Tacrine; Time Factors; Tremor | 2014 |
Treadmill exercise modulates nigral and hippocampal cannabinoid receptor type 1 in the 6-OHDA model of Parkinson's disease.
Topics: Animals; Corpus Striatum; Disease Models, Animal; Drug Inverse Agonism; Hippocampus; Male; Oxidopamine; Parkinson Disease; Rats; Rats, Wistar; Receptors, Cannabinoid; Rimonabant; Substantia Nigra | 2023 |